Neurogene Inc. (NASDAQ:NGNE) Shares Sold by Janus Henderson Group PLC

Janus Henderson Group PLC decreased its position in shares of Neurogene Inc. (NASDAQ:NGNE) by 3.4% during the 1st quarter, HoldingsChannel reports. The institutional investor owned 813,353 shares of the company’s stock after selling 28,335 shares during the quarter. Janus Henderson Group PLC owned about 0.06% of Neurogene worth $41,369,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. SG Americas Securities LLC purchased a new stake in shares of Neurogene in the first quarter valued at about $120,000. Privium Fund Management UK Ltd acquired a new stake in Neurogene in the first quarter valued at $274,000. BML Capital Management LLC purchased a new stake in shares of Neurogene during the 4th quarter worth $478,000. Avidity Partners Management LP acquired a new stake in shares of Neurogene in the fourth quarter valued at about $9,036,000. Finally, Great Point Partners LLC acquired a new position in Neurogene during the fourth quarter worth about $19,268,000. Hedge funds and other institutional investors own 52.37% of the company’s stock.

Wall Street Analyst Weigh In

NGNE has been the topic of several research analyst reports. HC Wainwright reissued a “buy” rating and set a $51.00 price target on shares of Neurogene in a research note on Thursday, June 20th. Leerink Partnrs reaffirmed an “outperform” rating on shares of Neurogene in a report on Monday, April 29th. SVB Leerink initiated coverage on Neurogene in a research report on Monday, April 29th. They issued an “outperform” rating and a $46.00 price objective on the stock. BMO Capital Markets assumed coverage on shares of Neurogene in a report on Thursday, June 27th. They set an “outperform” rating and a $65.00 price target for the company. Finally, Robert W. Baird started coverage on shares of Neurogene in a research report on Tuesday, June 11th. They set an “outperform” rating and a $54.00 target price on the stock. Eight research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, Neurogene has a consensus rating of “Buy” and an average price target of $51.33.

Neurogene Stock Up 0.8 %

NGNE stock traded up $0.30 on Wednesday, hitting $39.42. 9,175 shares of the company’s stock traded hands, compared to its average volume of 123,198. The stock has a fifty day moving average of $37.55 and a 200-day moving average of $35.94. Neurogene Inc. has a 1-year low of $12.20 and a 1-year high of $53.00.

Neurogene (NASDAQ:NGNE) last announced its quarterly earnings data on Friday, May 10th. The company reported ($1.00) EPS for the quarter, beating analysts’ consensus estimates of ($1.03) by $0.03. Equities research analysts forecast that Neurogene Inc. will post -4.15 earnings per share for the current fiscal year.

Neurogene Company Profile

Neurogene Inc, a biotechnology company, develops genetic medicines for rare neurological diseases. The company's product candidates include NGN-401 which is packaged in an adeno-associated virus 9 that is in Phase 1/2 clinical trial for the treatment of Rett syndrome; and NGN-101, a conventional gene therapy candidate that is in Phase 1/2 clinical trial to treat CLN5 Batten disease.